Takeda, Intra-Cellular Ink Global Co-Development Deal For PDE1 Inhibitors For Schizophrenia
This article was originally published in The Pink Sheet Daily
Deal for preclinical compounds includes undisclosed upfront payment and up to $750 million in milestones.
You may also be interested in...
Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.